13,300 Shares in ADC Therapeutics SA (NYSE:ADCT) Acquired by Kazazian Asset Management LLC

Kazazian Asset Management LLC purchased a new position in shares of ADC Therapeutics SA (NYSE:ADCT) during the 4th quarter, according to its most recent 13F filing with the SEC. The firm purchased 13,300 shares of the company’s stock, valued at approximately $26,000.

Several other institutional investors and hedge funds have also bought and sold shares of ADCT. Intech Investment Management LLC bought a new position in ADC Therapeutics during the 3rd quarter worth approximately $41,000. Charles Schwab Investment Management Inc. grew its position in shares of ADC Therapeutics by 10.7% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 194,258 shares of the company’s stock worth $612,000 after buying an additional 18,796 shares during the last quarter. FMR LLC bought a new stake in shares of ADC Therapeutics in the 3rd quarter worth approximately $167,000. MetLife Investment Management LLC grew its position in shares of ADC Therapeutics by 129.1% in the 3rd quarter. MetLife Investment Management LLC now owns 43,089 shares of the company’s stock worth $136,000 after buying an additional 24,279 shares during the last quarter. Finally, Redmile Group LLC grew its position in shares of ADC Therapeutics by 2.6% in the 3rd quarter. Redmile Group LLC now owns 15,669,217 shares of the company’s stock worth $49,358,000 after buying an additional 400,000 shares during the last quarter. 41.10% of the stock is currently owned by institutional investors.

ADC Therapeutics Stock Down 1.4 %

NYSE ADCT opened at $1.77 on Wednesday. ADC Therapeutics SA has a twelve month low of $1.39 and a twelve month high of $5.38. The firm has a market capitalization of $170.66 million, a PE ratio of -0.74 and a beta of 1.51. The stock’s 50 day moving average is $1.70 and its 200 day moving average is $2.32.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on the company. HC Wainwright reiterated a “buy” rating and issued a $8.00 price objective on shares of ADC Therapeutics in a research report on Monday, January 6th. Cantor Fitzgerald reiterated an “overweight” rating on shares of ADC Therapeutics in a research report on Friday, March 7th. Stephens lifted their price objective on ADC Therapeutics from $6.00 to $8.00 and gave the stock an “overweight” rating in a research report on Monday, February 24th. Finally, Guggenheim reiterated a “buy” rating and issued a $10.00 price objective on shares of ADC Therapeutics in a research report on Thursday, December 12th. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company has a consensus rating of “Buy” and an average price target of $8.50.

About ADC Therapeutics

ADC Therapeutics SA focuses on advancing its proprietary antibody drug conjugate (ADC) technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. Its flagship product is ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S.